Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 01; Document no.: EOC210302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc289
Jagwani, M; Badea, A; Groot, G; Mueller, M; Young, C. What are the causes of vaccine hesitancy? What programs/approaches have been successful in reducing vaccine hesitancy? 2021 Aug 17. Document no.: EOC012201v3 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc298
Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 15 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc299
Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc300
Young, C; Mueller, M. What are the causes of vaccine hesitancy? What programs/approaches have been successful in reducing vaccine hesitancy? 2021 Aug 11, Document no.: EOC012201v3 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 26 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc355
Jagwani, M; Badea, A; Groot, G; Mueller, M; Young, C. What are the causes of vaccine hesitancy? What programs/approaches have been successful in reducing vaccine hesitancy? 2021 Aug 17 Document no.: EOC012201v3 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 15 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc362
Miller, L., Howell-Spooner, B. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Sep 29, Document no.: EOC210902 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc375
What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? No citation available. https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc381
Badea, A; Groot, G; Muhajarine, N; Lee, S; Shumilak, G; Hernandez-Ronquillo, L; Tian, K. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Oct 07, Document no.: EOC210902 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 8 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc383
Mueller, M; Dalidowicz, M. Long COVID: What does it mean for the healthcare system and programs to? 2021 Oct 21, Document no.: EOC021901v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 70 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc386
Williams-Roberts, H; Groot, G; Mueller, M; Dalidowicz, M. Long COVID: What does it mean for the healthcare system and programs? 2021 Oct 29. Document no.: EOC021901v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST Table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc397
Williams-Roberts, H; Groot, G; Mueller, M; Dalidowicz, M. Long COVID: What does it mean for the healthcare system and programs? 2021 Oct 29. Document no.: EOC021901v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc398
Miller, L; Mueller, M. What are the one year outcomes for ICU COVID patients? 2022 Feb 10. Document no.: EOC220201 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 46 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc440
Badea, A; Reeder, B; Groot, G; Miller, L; Mueller, M. What are the one year outcomes for ICU COVID patients? 2022 Feb 18, Document no.: EOC220201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc446
Badea, A; Reeder, B; Groot, G; Miller, L; Mueller, M. What are the one year outcomes for ICU COVID patients? 2022 Feb 18, Document no.: EOC220201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc447
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Howell-Spooner, B. What is the efficacy of a 4th booster dose for COVID-19? 2022 Jun 7. Document no.: EOC220304v002 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc463
Rowein S, Singh S, Habbick M, Mehdiyeva K, Miller L, Gagneur, A, Groot G, Neudorf C, Camillo CA, Tokhmafshan, F, Muhajarine N. Motivational Interviewing for Vaccine Hesitancy. May 2022. Document no.: [12.1]. CoVaRR-Net Public Health, Health Systems, Social Policy Team, c2022. https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc487
Dalidowicz, M; Howell-Spooner, B. What is the efficacy of a 4th booster dose for COVID-19? 2022 May 27, Document no.: EOC220304v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 23 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc493
Badea, A; Dalidowicz, M; Howell-Spooner, B; Groot, G; Reeder. B. What is the efficacy of a 4th booster dose for COVID-19? 2022 Jun 07. Document no.: EOC220304v002 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc500
Hammond, B; Dalidowicz, M; Miller L; Groot, G; Reeder, B. Response to Long COVID: What are the Programs or accommodations to current frameworks? 2022 Jun 30. Document no.: EOC220303 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 21 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc507